JeanMarie Guenot is president and CEO of Amphivena Therapeutics, Inc., a company that develops bifunctional antibody therapies that can be used in the treatment of hematological malignancies.
Jeanmarie Guenot has over 20 years of experience in the biotechnology and pharmaceutical industry and it is her passion. She has experience involving all stages of project and alliance management, venture capital, commercial and corporate development, business development, and pharmaceutical research. Prior to becoming President and CEO of Amphivena Therapeutics, JeanMarie Guenot built SKS Ocular. This was a a start-up ophthalmic company incubator that primarily focused on muscular degeneration, ocular inflammation, glaucoma therapeutics, and the technology to support sustained ocular drug administration.
Geunot was a business advisor for Hoffmann-La Roche in Shanghai and in Basel and in 2003 she joined PDL Biopharma before becoming the Vice President of Corporate and Business Development in 2005. As Vice President, she was able to lead alliance management, mergers and acquisitions, and was able to get licensing taken care of for the company’s commercial products and research portfolios.
All her hard work had not gone unnoticed and JeanMarie Guenot was awarded 2005 BioBusiness Network’s Innovative Bio-Partnering award. She also received the Licensing Executive Society’s Deal of Distinction Award in 2006 on guenotllc.com.
Guenot has an extensive portfolio that includes experience in alliance and management with ophthalmic and neurology disease, cardiovascular diseases, autoimmune diseases, and oncology. Her career began with Atlas Venture where she provided financing for the early stages for life science. She also built life science companies and managed venture capital investments.
Geunot’s career began in the scientific field when she joined Hoffmann-La Roche in preclinical research and development. She worked there as a principal scientist and was in charge of discovering and developing drugs to treat inflammation, oncology, autoimmune diseases, and metabolic diseases. She is trained in physical chemistry and medicinal chemistry. Her main focus was on semi-empirical and quantum mechanical methods for protein structure prediction, drug design, and nuclear magnetic resonance. Guenot began working for Harpoon Therapeutics, Inc. in 2014 and in 2016 she was one of the co-founders of Maverick Therapeutics-a spin-off company of Harpoon Therapeutics.
Read more: Collaboration to Advance T-Cell Engagement Therapies